Teva Pharmaceutical Industries (TEVA) 44.18 0.01

Teva Pharmaceutical Industries
(TEVA) 44.18 0.01

Last Trade:	44.17	Day Range:	43.95 - 44.40
Trade Time:	11:02AM	52wk Range:	35.00 - 52.35
Prev. Close:	44.16	Market Cap:	41.56B
Open:	44.35	Div Yield:	1.95
Volume:	1543606	PE:
EPS:	0.00

The Latest On TEVA

Seven Hot Indian Stocks 2/8/12 6:25am

UPDATE: Morgan Stanley Downgrades Teva Pharmaceuticals to Equal-Weight 2/6/12 7:51am

Benzinga's Top Downgrades 2/6/12 7:44am

Financial Breakfast: Morning News Summary for February 06, 2012 2/6/12 7:27am

Morgan Stanley Downgrades Teva Pharmaceutical to Equal-weight 2/6/12 6:04am

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12 8:50am

Top Performing Health Care Stocks in January 2/1/12 6:32am

UPDATE: Goldman Sachs Raises Target to $48 on Teva 1/26/12 12:15pm

TooNiceStocks Starts Coverage of BioSante Ahead of FDA Decision 1/17/12 12:32pm

San Francisco Health Care Conferences Provide Plenty of Buzz and Chatter 1/13/12 6:26am

42 Dividend Contenders for Above-Average Total Return 1/12/12 10:02am

Benzinga's Top Pre-Market Losers 1/10/12 8:13am

Seven Hot Indian Stocks 2/8/12

UPDATE: Morgan Stanley Downgrades Teva Pharmaceuticals to Equal-Weight 2/6/12

Benzinga's Top Downgrades 2/6/12

Financial Breakfast: Morning News Summary for February 06, 2012 2/6/12

Morgan Stanley Downgrades Teva Pharmaceutical to Equal-weight 2/6/12

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12

Top Performing Health Care Stocks in January 2/1/12

UPDATE: Goldman Sachs Raises Target to $48 on Teva 1/26/12

TooNiceStocks Starts Coverage of BioSante Ahead of FDA Decision 1/17/12

San Francisco Health Care Conferences Provide Plenty of Buzz and Chatter 1/13/12

42 Dividend Contenders for Above-Average Total Return 1/12/12

Benzinga's Top Pre-Market Losers 1/10/12

Seven Hot Indian Stocks 2/8/12

Financial Breakfast: Morning News Summary for February 06, 2012 2/6/12

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12

Top Performing Health Care Stocks in January 2/1/12

TooNiceStocks Starts Coverage of BioSante Ahead of FDA Decision 1/17/12

42 Dividend Contenders for Above-Average Total Return 1/12/12

Can This Pharmaceutical Company Make You Rich? 1/6/12

Whatever Happened to...The Israel ETF? 12/21/11

Benzinga's M&A Chatter for Friday December 9, 2011 12/9/11

Are You Guaranteed Profits if These Rumors are True? 12/9/11

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms 12/7/11

After Today, Plan B Emergency Contraceptive Pill May Appear On Shelves Next to Aspirin 12/7/11

UPDATE: Morgan Stanley Downgrades Teva Pharmaceuticals to Equal-Weight 2/6/12

Benzinga's Top Downgrades 2/6/12

Financial Breakfast: Morning News Summary for February 06, 2012 2/6/12

Morgan Stanley Downgrades Teva Pharmaceutical to Equal-weight 2/6/12

UPDATE: Goldman Sachs Raises Target to $48 on Teva 1/26/12

TooNiceStocks Starts Coverage of BioSante Ahead of FDA Decision 1/17/12

JP Morgan Views New CEO for Teva Pharmaceuticals as Positive 1/3/12

Jefferies Reiterates Hold, $43 Target on Teva 12/23/11

Deutsche Bank Reiterates Buy, $48 Target on Teva Pharmaceuticals 12/22/11

Piper Jaffray Reiterates Neutral, PT of $45 on Teva Pharmaceuticals 12/22/11

Deutsche Bank Raises PT on Teva Pharma to $48 12/22/11

Morgan Stanley Maintains Overweight on Teva Pharma Despite Guidance Miss 12/21/11

Trade TEVA
NOW!

Partner Headlines

Analysts' Actions: FDX, BWLD, GILD, MGM 2/6/12

The Stock Making Buffett's Pals at the Sequoia Fund Rich: Valeant Pharmaceuticals 2/1/12

Ken Fisher and the Price to Research Ratio 2/1/12

Valeant Withdraws ISTA Offer - Analyst Blog 1/31/12

Label Expansion for Merck KGaA Drug - Analyst Blog 1/27/12

Gilead, Celgene Join Big Pharma On M&A Front 1/27/12

Diversified Investment Appeal From Novartis (NVS, GSK, MRK, TEVA) 1/27/12

Momenta Plunges As Lovenox Fight Tilts Toward Watson 1/26/12

Zacks Bull and Bear of the Day Highlights: DaVita, Hhgregg, Mylan, Teva Pharmaceutical and Novartis - Press Releases 1/25/12

Medicines Co. Settles with APP - Analyst Blog 1/24/12

Press Releases

ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO 1/23/12 GlobeNewswire Story

Teva to Report Fourth Quarter and Full Year 2011 Financial Results on February 15, 2012 1/16/12 Business Wire Story

Critical Alerts for Verizon Communications Inc. (VZ), Baker Hughes Incorporated (BHI), Teva Pharmaceutical Industries Limited (TEVA), SunTrust Banks, Inc. (STI), and Polaris Industries, Inc. (PII) Released by Seven Summits Research 1/12/12 Newswire Story

Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference 1/9/12 Business Wire Story

Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE® 1/3/12 Business Wire Story

Teva Announces Management Succession 1/1/12 Business Wire Story

Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe 12/22/11 Business Wire Story

Teva Provides 2012 Non-GAAP Financial Outlook; 2012 Non-GAAP Diluted EPS of $5.48 to $5.68 12/21/11 Business Wire Story

Teva Announces $3 billion Share Repurchase Program 12/21/11 Business Wire Story

Teva to Host 2012 Business Outlook Conference Call 12/13/11 Business Wire Story

Teva to Present at the NASDAQ OMX 27th Investor Program 12/5/11 Business Wire Story

CORRECTING and REPLACING Teva Announces Tentative Approval of Generic Lipitor® 12/1/11 Business Wire Story

Get the latest TEVA stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Teva Pharmaceutical Industries stock price.

Teva Pharmaceutical Industries by YCharts